Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) reduce binge eating frequency and severity in patients with Binge Eating Disorder (BED) and Bulimia Nervosa (BN), likely by modulating central reward circuits and increasing satiety.

If you have BED or BN, GLP-1RAs like semaglutide or liraglutide can significantly reduce binge eating episodes by changing how your brain responds to food rewards and increasing fullness. This is supported by systematic reviews, though it is not a standalone cure and should be monitored by a clinician, especially given potential gastrointestinal side effects.

GLP-1 receptor agonists (semaglutide, tirzepatide) are highly effective pharmacologic interventions for obesity, producing significant weight loss and metabolic improvements, but their rapid expansion raises safety concerns regarding gastrointestinal side effects, rare serious adverse events, and long-term outcomes not captured in clinical trials.

GLP-1 medications like semaglutide and tirzepatide are currently the most effective non-surgical treatments for obesity, offering weight loss comparable to surgery for many. However, they are not without risks, including common gastrointestinal issues and rare serious side effects. It is crucial to use these medications under strict medical supervision, especially if you have other health conditions, to manage side effects and monitor for long-term safety.

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to either component alone, but are limited by a low GLP-1RA dose relative to the insulin dose, making separate dosing preferable for obese patients requiring higher GLP-1RA doses.

Fixed-ratio combinations (like IDegLira, iGlarLixi, or IcoSema) are effective for lowering blood sugar and weight compared to using just insulin or just a GLP-1 drug. However, because the ratio of insulin to GLP-1 drug is fixed, these combinations often deliver too little GLP-1 drug for obese patients who need higher doses for maximum weight loss and glucose control. If you are obese or need high doses of GLP-1RA, separate injections of basal insulin and GLP-1RA allow you to titrate each drug independently to your optimal dose.

Antiobesity medications (AOMs) improve cardiovascular outcomes, hypertension, and metabolic liver disease in older adults, but their use requires caution due to an increased risk of sarcopenia.

For older adults, AOMs are a powerful tool to treat obesity-related health issues like heart disease and diabetes. However, because losing weight can also lead to muscle loss (sarcopenia), these medications should be used cautiously and monitored closely by a doctor, often alongside lifestyle changes.

Higher postprandial endogenous GLP-1 release is positively correlated with hepatic and peripheral insulin sensitivity in individuals with class II/III obesity without diabetes, and this association persists one year after Roux-en-Y gastric bypass (RYGB).

For individuals with obesity, higher natural GLP-1 responses to meals are linked to better insulin sensitivity. While Roux-en-Y gastric bypass significantly amplifies this GLP-1 response, leading to improved metabolic health, the study suggests that the magnitude of this hormonal response is a key indicator of metabolic status. Non-surgical strategies that might support healthy incretin responses (though not explicitly detailed in this paper) could be beneficial, but the data strongly links the specific postprandial GLP-1 profile to insulin sensitivity.

Shifting nutrient absorption to the distal small intestine (ileum) significantly increases post-prandial GLP-1 and PYY secretion, improving glucose control and contributing to weight loss, as seen in bariatric surgery and with certain enzyme inhibitors.

Bariatric surgery works partly by forcing food to be digested further down the intestine, which triggers a strong hormone release (GLP-1/PYY) that helps control blood sugar and appetite. Some diabetes medications (like acarbose) mimic this by slowing digestion. This suggests that how and where food is absorbed matters as much as what is eaten.

GLP-1 receptor agonists (GLP-1RA) significantly reduce body weight and visceral fat, leading to improved cardiovascular and renal outcomes in T2DM patients.

For T2DM patients with heart or kidney risks, GLP-1 receptor agonists are a top choice. They help lower blood sugar, promote significant weight loss by reducing visceral fat, and protect the heart and kidneys. Discuss options like weekly injections or oral formulations with your doctor.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) reduce cardiovascular risk and may induce atherosclerotic plaque regression in patients with diabetes-associated atherosclerosis.

If you have diabetes and heart disease risk, ask your doctor about GLP-1 agonists like liraglutide or semaglutide. They don't just lower blood sugar; they protect your heart and may shrink arterial plaques. These are injectable drugs, but they offer significant cardiovascular benefits that oral medications may not.

The presence of obesity-related complications (e.g., Type 2 Diabetes, Hypertension) significantly amplifies medical costs, with costs up to 5.2 times higher for those with multiple complications compared to obesity alone.

Having obesity-related complications like Type 2 Diabetes or Hypertension drastically increases medical costs (up to 5.2x). This underscores the importance of not just losing weight, but also managing these specific conditions to control overall healthcare spending.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity (measured by AHI) and improves cardiometabolic risk factors in patients with obesity and moderate-to-severe OSA.

If you have obesity and moderate-to-severe sleep apnea, Tirzepatide is a newly approved medication that can significantly reduce the severity of your apnea (AHI) and improve blood pressure and inflammation. It works primarily by promoting weight loss and potentially affecting brain pathways related to breathing control. Because stopping the drug leads to weight regain, it is likely a long-term treatment. It is not a substitute for PAP therapy in all cases, but it is a powerful new tool, especially for those who struggle with CPAP adherence.

Long-term use of FDA-approved GLP-1/GIP agonists (tirzepatide and semaglutide) produces significant weight loss and metabolic improvements in real-world populations, though efficacy is lower than in randomized clinical trials due to conservative dosing and adherence issues.

Tirzepatide and semaglutide are highly effective for weight loss in real-world settings, but results vary. Expect that only about 1/3 to 2/5 of users will lose 10% of their body weight, even with long-term use. This is lower than clinical trial promises due to lower real-world doses and adherence. Consistency and appropriate dosing are key.

Discontinuation of FDA-approved GLP-1/GIP agonists (tirzepatide, semaglutide) does not lead to significant weight regain at the population level, contrasting with off-label drugs like phentermine and zonisamide which cause substantial regain.

If you stop taking tirzepatide or semaglutide, you are not guaranteed to regain all the weight immediately. Studies show that some weight loss benefit may persist for up to two years. This is different from older drugs like phentermine, where regain is common.

Achieving diabetes remission in type 2 diabetes patients reduces the risk of cardiovascular disease by approximately 30% compared to non-remission, independent of significant weight loss.

For patients with type 2 diabetes, achieving remission (normal blood glucose without medication) is a critical goal for preventing heart disease. This benefit exists even if you do not lose significant weight, suggesting that metabolic improvements (like reduced liver/pancreas fat) are key. Focus on achieving remission through available treatments rather than solely on weight loss metrics.

Continuous Glucose Monitoring (CGM) reveals that postprandial hypoglycemia is significantly more prevalent (up to 75%) than previously thought, with a large proportion of episodes being asymptomatic.

Standard blood tests might miss hypoglycemia after gastric bypass. If you are at risk, ask your doctor about Continuous Glucose Monitoring (CGM) to detect silent low blood sugar episodes that could affect your brain health.

Habitual endurance or resistance exercise training enhances insulin-stimulated glycogen synthesis in primary human skeletal muscle stem cells compared to sedentary controls, but does not confer intrinsic protection against fatty acid-induced insulin resistance.

If you are highly active, your skeletal muscle cells are better at storing glucose as glycogen when insulin is present, regardless of whether you primarily do cardio or weight training. However, this cellular adaptation does not appear to protect your muscle cells from the negative effects of high fat exposure in a lab setting. To maximize metabolic health, maintain high activity levels, but be aware that cellular adaptations to training may not fully shield you from all metabolic insults like high lipid loads.

Treatment with maximal-tolerated dose tirzepatide (10-15 mg weekly) for 72 weeks produces substantial weight loss and health risk reduction, but typically fails to return average Class II obese individuals to the healthy BMI (<25 kg/m2) or healthy Body Roundness Index (BRI) ranges.

If you are taking tirzepatide at a high dose, expect significant health improvements and weight loss, but do not expect to automatically reach a 'healthy' BMI of under 25. The average patient in the major trials remains in the overweight or obese category even after a year. Focus on the reduction in health risks (like visceral fat/BRI) rather than just hitting a specific BMI number.

Semaglutide 2.4 mg weekly significantly improves symptoms, functional capacity, and reduces systemic inflammation in obese patients with heart failure with preserved ejection fraction (HFpEF).

If you have heart failure with preserved ejection fraction and are obese, ask your doctor about semaglutide. It is a once-weekly injection that has been shown to significantly improve your heart failure symptoms, exercise capacity, and reduce inflammation. While it may cause temporary stomach issues, the benefits for your heart and weight are substantial.

Genetic variation in the NBEA gene predicts weight loss response to GLP-1 receptor agonists (GLP-1RAs), with specific NBEA scores identifying individuals likely to be highly responsive or non-responsive to treatment.

If you are prescribed a GLP-1RA like semaglutide or liraglutide, ask your doctor about genetic testing for the NBEA gene. This test can predict whether you are likely to lose significant weight (top 20% responders) or not respond at all. This helps avoid wasting time and money on medications that are unlikely to work for your specific biology, allowing for a more personalized and effective obesity treatment plan.

Achieving ≥20–25% early postoperative weight loss (EWL) within the first 3–6 months after bariatric surgery strongly predicts sustained long-term weight loss (≥50% EWL) and metabolic remission.

If you had bariatric surgery, your weight loss in the first 3-6 months is a major predictor of your long-term success. Aim for at least 20-25% excess weight loss in this window. If you are slower, do not give up; this is a signal for your medical team to intensify support (nutrition, behavioral therapy, or medication) to help you catch up.

Semaglutide 2.4 mg is recommended for secondary prevention of cardiovascular events in individuals with BMI ≥27 kg/m² without diabetes but with established cardiovascular disease.

If you have established heart disease, are overweight (BMI ≥27), and do not have diabetes, ask your doctor about semaglutide 2.4 mg. This medication is recommended to help prevent future heart attacks, strokes, and cardiovascular death.

Bariatric surgery (VSG and RYGB) improves metabolic health and promotes weight loss by altering gut microbiota to increase the production of specific metabolites (licoricidin and butyrate) that activate thermogenesis in adipose tissue.

Bariatric surgery's success is largely due to how it changes your gut bacteria to burn more fat, not just by making you eat less. This suggests that targeting gut health and metabolism could be key to treating obesity, potentially leading to new non-surgical treatments.

Caloric restriction interventions restore gut-brain axis communication in obesity by enriching beneficial bacteria (e.g., Akkermansia muciniphila), reducing LPS-mediated endotoxemia, and modulating SCFA production to enhance satiety signaling.

To leverage the gut-brain axis for weight management, reduce your daily caloric intake by 20-40% while ensuring you get adequate nutrients. This specific type of dietary restriction has been shown to improve gut bacteria diversity, reduce inflammation, and boost satiety hormones, making it easier to maintain energy balance.

Obesity is associated with gut microbiota dysbiosis characterized by reduced diversity, altered taxonomic abundance, and impaired gut-brain axis communication, leading to dysregulated appetite and energy homeostasis.

Obesity is linked to changes in gut bacteria that disrupt signals for hunger and fullness. These changes include lower bacterial diversity and reduced production of satiety hormones. Understanding this link highlights why dietary changes can help reset these signals.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors reduce cardiovascular events and improve liver histology in MASLD patients, particularly those with type 2 diabetes or obesity.

If you have MASLD and diabetes or obesity, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT2 inhibitors. These drugs not only help control blood sugar and weight but also significantly lower the risk of heart attacks and strokes, and may improve liver health. They are safe for use in MASLD patients within their approved indications.